135 related articles for article (PubMed ID: 9539581)
1. Clinical impact of implementing the recommendations of AAPM Task Group 43 on permanent prostate brachytherapy using 125I. American Association of Physicists in Medicine.
Bice WS; Prestidge BR; Prete JJ; Dubois DF
Int J Radiat Oncol Biol Phys; 1998 Mar; 40(5):1237-41. PubMed ID: 9539581
[TBL] [Abstract][Full Text] [Related]
2. Recommendations of the American Association of Physicists in Medicine regarding the impact of implementing the 2004 task group 43 report on dose specification for 103Pd and 125I interstitial brachytherapy.
Williamson JF; Butler W; Dewerd LA; Huq MS; Ibbott GS; Mitch MG; Nath R; Rivard MJ; Todor D;
Med Phys; 2005 May; 32(5):1424-39. PubMed ID: 15984693
[TBL] [Abstract][Full Text] [Related]
3. American Brachytherapy Society recommends no change for prostate permanent implant dose prescriptions using iodine-125 or palladium-103.
Rivard MJ; Butler WM; Devlin PM; Hayes JK; Hearn RA; Lief EP; Meigooni AS; Merrick GS; Williamson JF
Brachytherapy; 2007; 6(1):34-7. PubMed ID: 17284383
[TBL] [Abstract][Full Text] [Related]
4. A method for implementing the American Association of Physicists in Medicine Task Group-43 dosimetry recommendations for 125I transperineal prostate seed implants on commercial treatment planning systems.
Luse RW; Blasko J; Grimm P
Int J Radiat Oncol Biol Phys; 1997 Feb; 37(3):737-41. PubMed ID: 9112474
[TBL] [Abstract][Full Text] [Related]
5. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer.
Nag S; Beyer D; Friedland J; Grimm P; Nath R
Int J Radiat Oncol Biol Phys; 1999 Jul; 44(4):789-99. PubMed ID: 10386635
[TBL] [Abstract][Full Text] [Related]
6. Review of AAPM Task Group No. 43 recommendations on interstitial brachytherapy sources dosimetry. American Association of Physicists in Medicine.
Saw CB; Meigooni AS; Nath R
Med Dosim; 1998; 23(4):259-63. PubMed ID: 9863722
[TBL] [Abstract][Full Text] [Related]
7. A survey of physics and dosimetry practice of permanent prostate brachytherapy in the United States.
Prete JJ; Prestidge BR; Bice WS; Friedland JL; Stock RG; Grimm PD
Int J Radiat Oncol Biol Phys; 1998 Mar; 40(4):1001-5. PubMed ID: 9531387
[TBL] [Abstract][Full Text] [Related]
8. AAPM TG-43 formalism for brachytherapy dose calculation of a 137Cs tube source.
Zhang P; Beddar AS; Sibata CH
Med Phys; 2004 Apr; 31(4):755-9. PubMed ID: 15124992
[TBL] [Abstract][Full Text] [Related]
9. Update of AAPM Task Group No. 43 Report: A revised AAPM protocol for brachytherapy dose calculations.
Rivard MJ; Coursey BM; DeWerd LA; Hanson WF; Huq MS; Ibbott GS; Mitch MG; Nath R; Williamson JF
Med Phys; 2004 Mar; 31(3):633-74. PubMed ID: 15070264
[TBL] [Abstract][Full Text] [Related]
10. A method for implementing the American Association of Physicists in Medicine Task Group-43 dosimetry recommendations for 125I transperineal prostate seed implants on commercial treatment planning systems: regarding Luse et al. IJROBP 37:737-741; 1997.
Rustgi SN
Int J Radiat Oncol Biol Phys; 1999 Aug; 45(1):243. PubMed ID: 10477029
[No Abstract] [Full Text] [Related]
11. Centralized multiinstitutional postimplant analysis for interstitial prostate brachytherapy.
Bice WS; Prestidge BR; Grimm PD; Friedland JL; Feygelman V; Roach M; Prete JJ; Dubois DF; Blasko JC
Int J Radiat Oncol Biol Phys; 1998 Jul; 41(4):921-7. PubMed ID: 9652858
[TBL] [Abstract][Full Text] [Related]
12. Potential role of various dosimetric quality indicators in prostate brachytherapy.
Merrick GS; Butler WM; Dorsey AT; Lief JH
Int J Radiat Oncol Biol Phys; 1999 Jun; 44(3):717-24. PubMed ID: 10348304
[TBL] [Abstract][Full Text] [Related]
13. Rectal dosimetric analysis following prostate brachytherapy.
Merrick GS; Butler WM; Dorsey AT; Lief JH; Walbert HL; Blatt HJ
Int J Radiat Oncol Biol Phys; 1999 Mar; 43(5):1021-7. PubMed ID: 10192350
[TBL] [Abstract][Full Text] [Related]
14. Dosimetry of (125)I and (103)Pd COMS eye plaques for intraocular tumors: report of Task Group 129 by the AAPM and ABS.
Chiu-Tsao ST; Astrahan MA; Finger PT; Followill DS; Meigooni AS; Melhus CS; Mourtada F; Napolitano ME; Nath R; Rivard MJ; Rogers DW; Thomson RM
Med Phys; 2012 Oct; 39(10):6161-84. PubMed ID: 23039655
[TBL] [Abstract][Full Text] [Related]
15. Isotope selection for patients undergoing prostate brachytherapy.
Cha CM; Potters L; Ashley R; Freeman K; Wang XH; Waldbaum R; Leibel S
Int J Radiat Oncol Biol Phys; 1999 Sep; 45(2):391-5. PubMed ID: 10487561
[TBL] [Abstract][Full Text] [Related]
16. Postimplant analysis of transperineal interstitial permanent prostate brachytherapy: evidence for a learning curve in the first year at a single institution.
Lee WR; deGuzman AF; Bare RL; Marshall MG; McCullough DL
Int J Radiat Oncol Biol Phys; 2000 Jan; 46(1):83-8. PubMed ID: 10656377
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of radiobiologic biochemical control in a large permanent prostate brachytherapy population from a single institution using AAPM TG-137 parameters.
Butler WM; Stewart RR; Merrick GS
Brachytherapy; 2011; 10(1):16-28. PubMed ID: 20149981
[TBL] [Abstract][Full Text] [Related]
18. A detailed radiobiological and dosimetric analysis of biochemical outcomes in a case-control study of permanent prostate brachytherapy patients.
Butler WM; Stewart RR; Merrick GS
Med Phys; 2009 Mar; 36(3):776-87. PubMed ID: 19378738
[TBL] [Abstract][Full Text] [Related]
19. Review of eye plaque dosimetry based on AAPM Task Group 43 recommendations. American Association of Physicists in Medicine.
Ray SK; Bhatnagar R; Hartsell WF; Desai GR
Int J Radiat Oncol Biol Phys; 1998 Jun; 41(3):701-6. PubMed ID: 9635722
[TBL] [Abstract][Full Text] [Related]
20. Timing of computed tomography-based postimplant assessment following permanent transperineal prostate brachytherapy.
Prestidge BR; Bice WS; Kiefer EJ; Prete JJ
Int J Radiat Oncol Biol Phys; 1998 Mar; 40(5):1111-5. PubMed ID: 9539566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
